Target
Src kinase
7 abstracts
Abstract
Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing.Org: University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, University of Colorado School of Medicine, Veterans Affairs Medical Center, University of Colorado Denver Anschutz Medical Center,
Abstract
Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.Org: University Hospital of Regensburg, University Medicine Greifswald, Pediatric Hematology and Oncology, University Medical Center Dresden, University of Jena, University Children's Hospital,
Abstract
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).Org: Medstar Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Dana-Farber Cancer Institute, AstraZeneca, Lombardi Comprehensive Cancer Center, Georgetown University,
Abstract
Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.Org: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Oncology Center of Excellence,
Abstract
Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.Org: University of California San Francisco, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Hackensack University Medical Center, Portland VA Health Care System and OHSU Knight Cancer Institute,
Abstract
AX-0085, a novel AXL kinase inhibitor, and effects on osimertinib-resistance in non–small-cell lung cancer.Org: Axceso Biopharma Co., Ltd., College of Medicine, Hanyang University, Department of Life Science, Ewha Research Center for Systems Biology, Ewha Womans University,
Abstract
Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models.Org: National Cancer Institute, Vilnius, Lithuania, University of Edinburgh Cancer Research UK Centre, Nuvectis Pharma,